11 results
Search Results
2. Targeting -Acetyl-GD2 Ganglioside for Cancer Immunotherapy.
- Author
-
Fleurence, Julien, Fougeray, Sophie, Bahri, Meriem, Cochonneau, Denis, Clémenceau, Béatrice, Paris, François, Heczey, Andras, Birklé, Stéphane, Clémenceau, Béatrice, and Birklé, Stéphane
- Subjects
- *
CANCER immunotherapy , *GANGLIOSIDES , *TARGETED drug delivery , *T cells , *ANTIGEN receptors , *MONOCLONAL antibodies , *THERAPEUTICS , *LIPID metabolism , *THERAPEUTIC use of monoclonal antibodies , *TUMOR treatment , *CELL receptors , *CLINICAL trials , *IMMUNOGLOBULINS , *IMMUNOTHERAPY , *LIPIDS , *METABOLISM , *TUMOR antigens , *TUMORS - Abstract
Target selection is a key feature in cancer immunotherapy, a promising field in cancer research. In this respect, gangliosides, a broad family of structurally related glycolipids, were suggested as potential targets for cancer immunotherapy based on their higher abundance in tumors when compared with the matched normal tissues. GD2 is the first ganglioside proven to be an effective target antigen for cancer immunotherapy with the regulatory approval of dinutuximab, a chimeric anti-GD2 therapeutic antibody. Although the therapeutic efficacy of anti-GD2 monoclonal antibodies is well documented, neuropathic pain may limit its application. O-Acetyl-GD2, the O-acetylated-derivative of GD2, has recently received attention as novel antigen to target GD2-positive cancers. The present paper examines the role of O-acetyl-GD2 in tumor biology as well as the available preclinical data of anti-O-acetyl-GD2 monoclonal antibodies. A discussion on the relevance of O-acetyl-GD2 in chimeric antigen receptor T cell therapy development is also included. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
3. Toll-Like Receptor-Based Strategies for Cancer Immunotherapy.
- Author
-
Pahlavanneshan, Saghar, Sayadmanesh, Ali, Ebrahimiyan, Hamidreza, and Basiri, Mohsen
- Subjects
IMMUNOTHERAPY ,TOLL-like receptors ,T cells ,GENETIC engineering ,IMMUNE response - Abstract
Toll-like receptors (TLRs) are expressed and play multiple functional roles in a variety of immune cell types involved in tumor immunity. There are plenty of data on the pharmacological targeting of TLR signaling using agonist molecules that boost the antitumor immune response. A recent body of research has also demonstrated promising strategies for improving the cell-based immunotherapy methods by inducing TLR signaling. These strategies include systemic administration of TLR antagonist along with immune cell transfer and also genetic engineering of the immune cells using TLR signaling components to improve the function of genetically engineered immune cells such as chimeric antigen receptor-modified T cells. Here, we explore the current status of the cancer immunotherapy approaches based on manipulation of TLR signaling to provide a perspective of the underlying rationales and potential clinical applications. Altogether, reviewed publications suggest that TLRs make a potential target for the immunotherapy of cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
4. Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions.
- Author
-
Ralli, Massimo, Botticelli, Andrea, Visconti, Irene Claudia, Angeletti, Diletta, Fiore, Marco, Marchetti, Paolo, Lambiase, Alessandro, de Vincentiis, Marco, and Greco, Antonio
- Subjects
IMMUNOTHERAPY ,MELANOMA ,T cells ,COMBINATION drug therapy ,IMMUNE recognition ,METASTASIS - Abstract
Melanoma is one of the most immunologic malignancies based on its higher prevalence in immune-compromised patients, the evidence of brisk lymphocytic infiltrates in both primary tumors and metastases, the documented recognition of melanoma antigens by tumor-infiltrating T lymphocytes and, most important, evidence that melanoma responds to immunotherapy. The use of immunotherapy in the treatment of metastatic melanoma is a relatively late discovery for this malignancy. Recent studies have shown a significantly higher success rate with combination of immunotherapy and chemotherapy, radiotherapy, or targeted molecular therapy. Immunotherapy is associated to a panel of dysimmune toxicities called immune-related adverse events that can affect one or more organs and may limit its use. Future directions in the treatment of metastatic melanoma include immunotherapy with anti-PD1 antibodies or targeted therapy with BRAF and MEK inhibitors. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
5. DNA Vaccine Treatment in Dogs Experimentally Infected with .
- Author
-
Arce-Fonseca, Minerva, Carbajal-Hernández, Ana C., Lozano-Camacho, Mónica, Carrillo-Sánchez, Silvia del C., Roldán, Francisco-Javier, Aranda-Fraustro, Alberto, Rosales-Encina, José Luis, and Rodríguez-Morales, Olivia
- Subjects
DNA vaccines ,TRYPANOSOMA cruzi ,CHAGAS' disease ,BEAGLE (Dog breed) ,DOGS ,HEART physiology ,PROTOZOA ,INTERLEUKINS ,BIOLOGICAL models ,MYOCARDIUM ,VACCINES ,IMMUNOGLOBULINS ,CELL culture ,ANIMAL experimentation ,INTERLEUKIN-1 ,CELL physiology ,TRYPANOSOMIASIS ,ELECTROCARDIOGRAPHY ,T cells ,IMMUNOTHERAPY - Abstract
Chagas disease is a chronic and potentially lethal disorder caused by the parasite Trypanosoma cruzi, and an effective treatment has not been developed for chronic Chagas disease. The objective of this study was to determine the effectiveness of a therapeutic DNA vaccine containing T. cruzi genes in dogs with experimentally induced Chagas disease through clinical, pathological, and immunological analyses. Infection of Beagle dogs with the H8 T. cruzi strain was performed intraperitoneally with 3500 metacyclic trypomastigotes/kg body weight. Two weeks after infection, plasmid DNA immunotherapy was administered thrice at 15-day intervals. The clinical (physical and cabinet studies), immunological (antibody and cytokine profiles and lymphoproliferation), and macro- and microscopic pathological findings were described. A significant increase in IgG and cell proliferation was recorded after immunotherapy, and the highest stimulation index (3.02) was observed in dogs treated with the pBCSSP4 plasmid. The second treatment with both plasmids induced an increase in IL-1, and the third treatment with the pBCSSP4 plasmid induced an increase in IL-6. The pBCSP plasmid had a good Th1 response regulated by high levels of IFN-gamma and TNF-alpha, whereas the combination of the two plasmids did not have a synergistic effect. Electrocardiographic studies registered lower abnormalities and the lowest number of individuals with abnormalities in each group treated with the therapeutic vaccine. Echocardiograms showed that the pBCSSP4 plasmid immunotherapy preserved cardiac structure and function to a greater extent and prevented cardiomegaly. The two plasmids alone controlled the infection moderately by a reduction in the inflammatory infiltrates in heart tissue. The immunotherapy was able to reduce the magnitude of cardiac lesions and modulate the cellular immune response; the pBCSP treatment showed a clear Th1 response; and pBCSSP4 induced a balanced Th1/Th2 immune response that prevented severe cardiac involvement. The pBCSSP4 plasmid had a better effect on most of the parameters evaluated in this study; therefore, this plasmid can be considered an optional treatment against Chagas disease in naturally infected dogs. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
6. Differentiation and Function of T Cell Subsets in Infectious Diseases.
- Author
-
Liang, Yuejin, Chen, Xiaojun, Chen, Jinling, and Liu, Fengliang
- Subjects
T cell differentiation ,COMMUNICABLE diseases ,DISEASE risk factors ,ANIMALS ,CELL differentiation ,CELL receptors ,HISTOCOMPATIBILITY antigens ,IMMUNITY ,IMMUNOTHERAPY ,T cells - Published
- 2018
- Full Text
- View/download PDF
7. New Insights for Immune-Based Diagnosis and Therapy for Infectious Diseases.
- Author
-
Sautto, Giuseppe A., Diotti, Roberta A., Wisskirchen, Karin, and Kahle, Kristen M.
- Subjects
COMMUNICABLE disease diagnosis ,IMMUNE system ,IMMUNOTHERAPY ,COMMUNICABLE disease treatment ,ANIMALS ,CELLULAR immunity ,COMMUNICABLE diseases ,IMMUNOGLOBULINS ,T cells ,VACCINES ,ANTIBODY formation - Published
- 2017
- Full Text
- View/download PDF
8. Distinct Changes of BTLA and HVEM Expressions in Circulating CD4+ and CD8+ T Cells in Hepatocellular Carcinoma Patients.
- Author
-
Liu, Jiayu, Li, Jiaqian, He, Min, Zhang, Geng-Lin, and Zhao, Qiyi
- Subjects
LIVER cancer ,T cells ,IMMUNOTHERAPY ,CD4 antigen ,B cells - Abstract
BTLA/HVEM (B and T lymphocyte attenuator/herpes virus entry mediator) pathways play a critical role in T cell suppression in tumor. However, its dynamic changes in different T cell subsets in peripheral blood and their clinical significance are largely unclear in cancer patients. In the current study, we showed distinct changes of BTLA and HVEM expressions on peripheral blood CD4+ and CD8+ T cells in patients with hepatocellular carcinoma (HCC); BTLA expression were significantly upregulated on circulating CD4+ but not CD8+ T cells. In sharp contrast, the levels of HVEM expression were significantly downregulated on circulating CD8+ but not CD4+ T cells. A strong positive correlation between BTLA expression on circulating CD4+ T cells and BTLA expression on autologous CD8+ counterparts was observed in healthy donors but absent in HCC patients. More importantly, we found that blockade of the BTLA/HVEM pathway increased IFN-γ production in both circulating CD4+ and CD8+ T cells. Collectively, our data suggested that the BTLA/HVEM pathway contributes to peripheral T cell suppression in HCC patients, and BTLA/HVEM may serve as attractive targets for HCC immunotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
9. Immunotherapies: Exploiting the Immune System for Cancer Treatment.
- Author
-
Koury, Jeffrey, Lucero, Mariana, Cato, Caleb, Chang, Lawrence, Geiger, Joseph, Henry, Denise, Hernandez, Jennifer, Hung, Fion, Kaur, Preet, Teskey, Garrett, and Tran, Andrew
- Subjects
IMMUNOTHERAPY ,CANCER treatment ,T cells ,CLINICAL trials ,CANCER prevention - Abstract
Cancer is a condition that has plagued humanity for thousands of years, with the first depictions dating back to ancient Egyptian times. However, not until recent decades have biological therapeutics been developed and refined enough to safely and effectively combat cancer. Three unique immunotherapies have gained traction in recent decades: adoptive T cell transfer, checkpoint inhibitors, and bivalent antibodies. Each has led to clinically approved therapies, as well as to therapies in preclinical and ongoing clinical trials. In this review, we outline the method by which these 3 immunotherapies function as well as any major immunotherapeutic drugs developed for treating a variety of cancers. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
10. The Role of TLR4 on B Cell Activation and Anti-2GPI Antibody Production in the Antiphospholipid Syndrome.
- Author
-
Cheng, Si, Wang, Haibo, and Zhou, Hong
- Subjects
- *
TOLL-like receptors , *B cells , *ANTIPHOSPHOLIPID syndrome , *GLUCOSE 6-phosphatase , *IMMUNOGLOBULINS , *PATIENTS , *ANTIPHOSPHOLIPID syndrome treatment , *ANTIGENS , *AUTOANTIBODIES , *CELL differentiation , *CELL receptors , *CELLULAR signal transduction , *DRUG therapy , *CYTOKINES , *GLYCOPROTEINS , *IMMUNITY , *IMMUNOLOGY technique , *IMMUNOTHERAPY , *T cells , *TUMOR necrosis factors , *ANTIBODY formation - Abstract
High titer of anti-β2-glycoprotein I antibodies (anti-β2GPI Ab) plays a pathogenic role in antiphospholipid syndrome (APS). Numerous studies have focused on the pathological mechanism in APS; however, little attention is paid to the immune mechanism of production of anti-β2GPI antibodies in APS. Our previous study demonstrated that Toll-like receptor 4 (TLR4) plays a vital role in the maturation of bone marrow-derived dendritic cells (BMDCs) from the mice immunized with human β2-glycoprotein I (β2GPI). TLR4 is required for the activation of B cells and the production of autoantibody in mice treated with β2GPI. However, TLR4 provides a third signal for B cell activation and then promotes B cells better receiving signals from both B cell antigen receptor (BCR) and CD40, thus promoting B cell activation, surface molecules expression, anti-β2GPI Ab production, and cytokines secretion and making B cell functioning like an antigen presenting cell (APC). At the same time, TLR4 also promotes B cells producing antibodies by upregulating the expression of B-cell activating factor (BAFF). In this paper, we aim to review the functions of TLR4 in B cell immune response and antibody production in autoimmune disease APS and try to find a new way for the prevention and treatment of APS. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
11. Peptide-Based Immunotherapeutics and Vaccines 2017.
- Author
-
Reche, Pedro, Flower, Darren R., Fridkis-Hareli, Masha, and Hoshino, Yoshihiko
- Subjects
IMMUNE system ,PEPTIDES ,VACCINES ,THERAPEUTICS ,ANIMALS ,ANTIGENS ,B cells ,IMMUNITY ,IMMUNIZATION ,IMMUNOTHERAPY ,INFECTION ,T cells - Published
- 2018
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.